Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2020

01-12-2020 | NSCLC | Review

Emerging therapeutic agents for advanced non-small cell lung cancer

Authors: Ruqin Chen, Rami Manochakian, Lauren James, Abdel-Ghani Azzouqa, Huashan Shi, Yan Zhang, Yujie Zhao, Kexun Zhou, Yanyan Lou

Published in: Journal of Hematology & Oncology | Issue 1/2020

Login to get access

Abstract

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanced NSCLC. In the last 10 years, the US Food and Drug Administration (FDA) has approved more than 17 new medications for this devastating disease and more are coming. Molecular and immunogenic testing makes personalized medicine possible for patients with advanced NSCLC. The new medications provide promising efficacy and safety resulting in improved long-term survival for a significant number of patients. In this review, we summarize the recent advances in advanced/metastatic NSCLC therapeutics with a specific focus on first in-human or early-phase I/II clinical trials. These drugs either offer better alternatives to current standard drugs in the same class or are a completely new class of drugs with novel mechanisms of action. Advances are divided into (1) targeted agents, (2) antibody-drug conjugates, and (3) immunotherapies. Finally, we present a brief review of the emerging agents and ongoing clinical studies.
Literature
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA: A Cancer Journal for Clinicians 2020, 70(1):7-30.
2.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899–909.CrossRef
3.
Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523–9.PubMedCrossRef
4.
Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–40.PubMedCrossRef
5.
Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–55.PubMedCrossRef
6.
Paz-Ares LG, Fd M, Dediu M, Thomas M, Pujol J-L, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer. Journal of Clinical Oncology. 2013;31(23):2895–902.PubMedCrossRef
7.
Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Janne PA, Johnson BE. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11(4):556–65.CrossRef
8.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRef
9.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.PubMedCrossRef
10.
Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. Journal of Clinical Oncology, 1684. 2018;36(17):1675.PubMedCrossRef
11.
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J, Eder JP, Balmanoukian AS, Aggarwal C, Horn L et al: Five-year overall survival for patients with advanced non–small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. Journal of Clinical Oncology, 0(0):JCO.19.00934.
12.
Kim D-W, Tan DS-W, Aix SP, Sequist LV, Smit EF, Hida T, Yang JC-H, Felip E, Seto T, Grohé C et al: Preliminary phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2018, 36(15_suppl):9094-9094.CrossRef
13.
Shi Y, Fang J, Shu Y, Wang D, Yu H, Zhao Y, Zhang L, Zhu B, Li X, Chen G et al: A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC. Journal of Clinical Oncology 2019, 37(15_suppl):9034-9034.CrossRef
14.
Ahn M-J, Han J-Y, Kim S-W, Lee KH, Kim D-W, Lee Y-G, Cho EK, Lee G-w, Lee J-S, Kim J-H et al: Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: updated results of phase I/II Study. Journal of Clinical Oncology 2019, 37(15_suppl):9037-9037.CrossRef
15.
Lu S, Camidge R, Yang C, Zhou J, Guo R, Chiu C, Chang G, Shiah H, Chen Y, Wang C et al: P1.01-62 The third generation irreversible EGFR inhibitor HS-10296 in advanced non-small cell lung cancer patients. Journal of Thoracic Oncology 2018, 13(10):S485.CrossRef
16.
Doebele RC, Riely GJ, Spira AI, Horn L, Piotrowska Z, Costa DB, Neal JW, Zhang S, Reichmann W, Kerstein D et al: First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC). Journal of Clinical Oncology 2018, 36(15_suppl):9015-9015.CrossRef
17.
Janne PA, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Horn L, Costa DB, Tsao AS, Patel JD, Gadgeel SM et al: Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Journal of Clinical Oncology 2019, 37(15_suppl):9007-9007.
18.
Piotrowska Z, Thress KS, Mooradian M, Heist RS, Azzoli CG, Temel JS, Rizzo C, Nagy RJ, Lanman RB, Gettinger SN et al: MET amplification (amp) as a resistance mechanism to osimertinib. Journal of Clinical Oncology 2017, 35(15_suppl):9020-9020.CrossRef
19.
Ma C, Wei S, Song Y: T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 2011, 3(1):10-18.
20.
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M: Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British journal of cancer 2019, 121(9):725-737.PubMedCrossRefPubMedCentral
21.
Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D et al: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 2020, 21(3):373-386.PubMedCrossRef
22.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
23.
Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ et al: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19(15):4273-4281.PubMedCrossRef
24.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371(23):2167-2177.PubMedCrossRef
25.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R et al: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017, 377(9):829-838.PubMedCrossRef
26.
Camidge DR, Peters S, Mok T, Gadgeel SM, Cheema PK, Pavlakis N, Marinis FD, Stroyakovskiy DL, Cho BC, Zhang L et al: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. Journal of Clinical Oncology 2018, 36(15_suppl):9043-9043.CrossRef
27.
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH et al: Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018, 379(21):2027-2039.PubMedCrossRef
28.
Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T et al: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017, 18(7):874-886.PubMedCrossRef
29.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM et al: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018, 19(12):1654-1667.PubMedCrossRef
30.
Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L et al: Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clinical cancer research : an official journal of the American Association for Cancer Research 2018, 24(12):2771-2779.PubMedPubMedCentralCrossRef
31.
Horn L, Wu Y-L, Reck M, Wakelee HA, Liang C, Tan F, Harrow K, Oertel V, Dukart G, Mok T: eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology 2018, 36(15_suppl):TPS9115-TPS9115.CrossRef
32.
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T et al: Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of oncology : official journal of the European Society for Medical Oncology 2019.
33.
Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY et al: Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 2017, 35(23):2613-2618.PubMedCrossRef
34.
Ou S, Shaw A, Riely G, Chiari R, Bauman J, Clancy J, Thurm H, Peltz G, Abbattista A, Solomon B: OA02.03 clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6. Journal of Thoracic Oncology 2018, 13(10):S322-S323.CrossRef
35.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018, 378(8):731-739.PubMedCrossRef
36.
Demetri GD, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, Kim ES, Blakely CM, Krauss JC, Sigal D et al: LBA4Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology 2018, 29(suppl_9).
37.
Siena S, Doebele RC, Shaw AT, Karapetis CS, Tan DS-W, Cho BC, Kim D-W, Ahn M-J, Krebs M, Goto K et al: Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. Journal of Clinical Oncology 2019, 37(15_suppl):3017-3017.CrossRef
38.
Papadopoulos KP, Gandhi L, Janne PA, Ou S-HI, Shaw A, Goldberg TR, Greenberg J, Gu X, Tachibana M, Senaldi G et al: First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. Journal of Clinical Oncology 2018, 36(15_suppl):2514-2514.CrossRef
39.
Drilon AE, Ou S-HI, Cho BC, Kim D-W, Lee J, Lin JJ, Zhu VW, Kim H, Kim TM, Ahn M-J et al: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). Journal of Clinical Oncology 2018, 36(15_suppl):2513-2513.CrossRef
40.
Cho BC, Drilon AE, Doebele RC, Kim D-W, Lin JJ, Lee J, Ahn M-J, Zhu VW, Ejadi S, Camidge DR et al: Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). Journal of Clinical Oncology 2019, 37(15_suppl):9011-9011.CrossRef
41.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18(10):1307–16.PubMedCrossRef
42.
Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg KB, Griffin N, Bijwaard K, Lee EY, Philip R, Jiang X, et al. FDA approval summary: dabrafenib and trametinib for the Treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist. 2018;23(6):740–5.PubMedPubMedCentralCrossRef
43.
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Janne PA, Verma S, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–30.PubMedCrossRef
44.
Camidge DR, Otterson GA, Clark JW, Ou S-HI, Weiss J, Ades S, Conte U, Tang Y, Wang SC-E, Murphy D et al: Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. Journal of Clinical Oncology 2018, 36(15_suppl):9062-9062.CrossRef
45.
Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–9.PubMedPubMedCentralCrossRef
46.
Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, Tan DS-W, Hida T, Jonge MJD, Orlov SV et al: Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Journal of Clinical Oncology 2019, 37(15_suppl):9004-9004.CrossRef
47.
Paik PK, Veillon R, Cortot AB, Felip E, Sakai H, Mazieres J, Griesinger F, Horn L, Senellart H, Meerbeeck JPV et al: Phase II study of tepotinib in NSCLC patients with METex14 mutations. Journal of Clinical Oncology 2019, 37(15_suppl):9005-9005.CrossRef
48.
Drilon A, Rekhtman N, Arcila M, Wang L, Ni A, Albano M, Van Voorthuysen M, Somwar R, Smith RS, Montecalvo J, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–60.PubMedPubMedCentralCrossRef
49.
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. The Lancet Respiratory medicine. 2017;5(1):42–50.PubMedCrossRef
50.
Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28(2):292–7.CrossRef
51.
V. Velcheti1 TH, K.L. Reckamp3, J.C. Yang4, H. Nokihara5, P. Sachdev6, K. Feit6, T. Kubota7, T. Nakada7: Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. Annals of oncology : official journal of the European Society for Medical Oncology 2016, 27(supplement 6):416-454.CrossRef
52.
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. Journal of Clinical Oncology. 2017;35(13):1403–10.PubMedPubMedCentralCrossRef
53.
A.E. Drilon SL, R. Doebele, C. Rodriguez, M. Fakih, K.L. Reckamp, L.1. Bazhenova, B.C. Cho, E. Kowack, J. Oliver, P. Multani, M. Ahn: A Phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC. Annals of Oncology 2017, 28(5): v605-v649.CrossRef
54.
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discovery. 2018;8(7):836–49.PubMedCrossRef
55.
Gainor JF, Lee DH, Curigliano G, Doebele RC, Kim D-W, Baik CS, Tan DS-W, Lopes G, Gadgeel SM, Cassier PA et al: Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2019, 37(15_suppl):9008-9008.CrossRef
56.
Drilon AE, Subbiah V, Oxnard GR, Bauer TM, Velcheti V, Lakhani NJ, Besse B, Park K, Patel JD, Cabanillas ME et al: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. Journal of Clinical Oncology 2018, 36(15_suppl):102-102.CrossRef
57.
Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer. 2017;123(21):4099–105.PubMedCrossRef
58.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. Journal of Clinical Oncology. 2018;36(24):2532–7.PubMedPubMedCentralCrossRef
59.
Iwata H, Tamura K, Doi T, Tsurutani J, Modi S, Park H, Krop IE, Sagara Y, Redfern CH, Murthy RK et al: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts. Journal of Clinical Oncology 2018, 36(15_suppl):2501-2501.CrossRef
60.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21.PubMedCrossRef
61.
Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J et al: Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European journal of cancer (Oxford, England : 1990) 2019, 109:28-35.PubMedPubMedCentralCrossRef
62.
Hamilton EP, Barve MA, Bardia A, Beeram M, Bendell JC, Mosher R, Hailman E, Bergstrom DA, Burris HA, Soliman HH: Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. Journal of Clinical Oncology 2018, 36(15_suppl):2546-2546.CrossRef
63.
Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Annals of oncology : official journal of the European Society for Medical Oncology. 2019;30(3):447–55.CrossRef
64.
Gao G, Li X, Wang Q, Zhang Y, Chen J, Shu Y, Hu Y, Fan Y, Fang J, Chen G et al: Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation. Journal of Clinical Oncology 2019, 37(15_suppl):9089-9089.CrossRef
65.
Govindan R FM, Price T, et al: Phase 1 study of safety, tolerability, P­­K and efficacy of AMG 510, a novel KRAS G12C inhibitor, evaluated in NSCLC. IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain Abstract OA0202 2019.
66.
Fakih M, O'Neil B, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Rasmussen E, Morrow PKH, Ngang J et al: Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. Journal of Clinical Oncology 2019, 37(15_suppl):3003-3003.CrossRef
67.
Christensen JG, Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR et al: The KRASG12C Inhibitor, MRTX849, Provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients. Cancer Discovery 2019:CD-19-1167.
68.
Plummer ER, Cook N, Arkenau H-T, Melear JM, Redfern CH, Spira AI, Chung KY, Shapiro G, Haddad TC, Ramalingam SS et al: Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2018, 36(15_suppl):e21048-e21048.CrossRef
69.
Sarantopoulos J, Beg MS, Fotopoulos G, Taverna JA, Anthony SP, Weitman SD, Warner SL, Mouritsen L, Bearss D, Smith S et al: A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):TPS2612-TPS2612.CrossRef
70.
Felip E, Brunsvig P, Vinolas N, Aix SP, Costa EC, Gomez MD, Perez JMT, Arriola E, Campelo RG, Spicer JF et al: A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. Journal of Clinical Oncology 2019, 37(15_suppl):9098-9098.CrossRef
71.
Rashdan S, Williams JN, Currykosky P, Fattah F, Padro J, Wnuk-Lipinska K, Gausdal G, Brown A, Micklem D, Holt RJ et al: A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC. Journal of Clinical Oncology 2018, 36(15_suppl):e21043-e21043.CrossRef
72.
Azaro A, Rodon J, Middleton MR, Baird RD, Herrmann R, Fiedler U, Haunschild J, Häuptle M, Hermann FJ, Schreiner S et al: First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):2520-2520.CrossRef
73.
AACR Project GENIE. Powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–31.CrossRef
74.
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(5):768–77.CrossRef
75.
Haura EB, Cho BC, Lee JS, Han J-Y, Lee KH, Sanborn RE, Govindan R, Cho EK, Kim S-W, Reckamp KL et al: JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2019, 37(15_suppl):9009-9009.CrossRef
76.
Sands JM, Shimizu T, Garon EB, Greenberg J, Guevara FM, Heist RS, Kobayashi F, Noguchi Y, Okajima D, Tajima N et al: First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors. Journal of Clinical Oncology 2019, 37(15_suppl):9051-9051.CrossRef
77.
Suresh S Ramalingam JL, Morten Mau-Sorensen, Fiona Thistlethwaite, Sarina Piha-Paul, Shirish Gadgeel, Yvette Drew, Pasi A Jänne, Aaron S. Mansfield, Guang Chen, Ulf Forssmann, Hrefna Kristin Johannsdottir, Nora Pencheva, Annette Ervin-Haynes, Ignace Vergote First-in-human phase 1/2 trial of anti-AXL antibody–drug conjugate (ADC) enapotamab vedotin (EnaV) in advanced NSCLC IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain Abstract OA0205.
78.
Sachdev JC, Maitland ML, Sharma M, Moreno V, Boni V, Kummar S, Stringer-Reasor EM, Forero-Torres A, Lakhani NJ, Gibson B et al: PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study. Journal of Clinical Oncology 2018, 36(15_suppl):5565-5565.CrossRef
79.
Adjei AA, Bekaii-Saab TS, Berlin J, Philip PA, Mercade TM, Walter A, Cupit L, Liu R, Fields SZ, Holynskyj A: Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. Journal of Clinical Oncology 2018, 36(15_suppl):TPS2607-TPS2607.CrossRef
80.
Ahnert JR, Taylor MH, O'Reilly EM, Zhang J, Doebele RC, Ben Y, Sharp LL, Boyle WJ, Chang C, Frey G et al: A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):TPS12126-TPS12126.CrossRef
81.
Banerji U, Cook N, Evans TRJ, Candilejo IM, Roxburgh P, Kelly CLS, Sabaratnam N, Passi R, Leslie S, Katugampola S et al: A cancer research UK phase I/IIa trial of BT1718 (a first in class bicycle drug conjugate) given intravenously in patients with advanced solid tumours. Journal of Clinical Oncology 2018, 36(15_suppl):TPS2610-TPS2610.CrossRef
82.
Janne PA, Yu HA, Johnson ML, Vigliotti M, Shipitofsky N, Guevara FM, Chen S, Yu C: Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC. Journal of Clinical Oncology 2018, 36(15_suppl):TPS9110-TPS9110.CrossRef
83.
Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. Journal of Cancer Metastasis and Treatment. 2017;3(10):250–61.CrossRef
84.
85.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature immunology. 2002;3(11):991–8.PubMedCrossRef
86.
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.PubMedPubMedCentralCrossRef
87.
Lopes G, Wu Y-L, Kudaba I, Kowalski D, Cho BC, Castro G, Srimuninnimit V, Bondarenko I, Kubota K, Lubiniecki GM et al: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Journal of Clinical Oncology 2018, 36(18_suppl):LBA4-LBA4.
88.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301.PubMedCrossRef
89.
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.PubMedCrossRef
90.
Wang J, Zhao J, Wang Z, Ma Z, Cui J, Shu Y, Liu Z, Cheng Y, Leaw S, Xia F et al: Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients. Journal of Clinical Oncology 2019, 37(15_suppl):e14067-e14067.CrossRef
91.
Moreno V, Calvo E, Garcia MEO, Gil-Martin M, Aljumaily R, Papadopoulos KP, Rosen LS, Rietschel P, Mohan KK, Li J et al: Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort. Journal of Clinical Oncology 2019, 37(8_suppl):116-116.CrossRef
92.
Yang J, Yang S, Song H, Han X, Han Y, Jiang S, Yao J, Zhang Z, Zhang S, Liu P et al: Phase 1 trial of JS001, a monoclonal antibody targeting programed death-1 (PD-1) in patients with advanced or recurrent malignancies. Journal of Clinical Oncology 2018, 36(15_suppl):e15108-e15108.CrossRef
93.
C. Lin MT, V. Boni, P.F. Brunsvig,et al: Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology (2018) 29 (suppl_8): viii400-viii441 101093/annonc/mdy288 2018.
94.
Vansteenkiste J, Felip E, Shepherd F, Paz-Ares L, Barlesi F, Burgers S, Cai C, Kiertsman F, Scott J, McCulloch T et al: P2.04-013 ElevatION:NSCLC-101; A phase 1b study of PDR001 combined with chemotherapy in PD-L1 unselected, metastatic NSCLC patients. Journal of Thoracic Oncology 2017, 12(11):S2402.CrossRef
95.
Zhou C, Gao G, Wang YN, Zhao J, Chen G, Liu Z, Gu K, Huang M, He J, Chen J et al: Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild-type EGFR and ALK. Journal of Clinical Oncology 2019, 37(15_suppl):9112-9112.CrossRef
96.
Siglec-15: An attractive immunotherapy Target. Cancer Discov 2020, 10(1):7-8.
97.
Lam VK, Hong DS, Heymach J, Blumenschein GR, Creelan BC, Bradbury PA, Butler MO, Gainor JF, Govindan R, Johnson ML et al: Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials. Journal of Clinical Oncology 2018, 36(15_suppl):3056-3056.CrossRef
98.
Sarnaik A, Khushalani NI, Chesney JA, Kluger HM, Curti BD, Lewis KD, Thomas SS, Whitman ED, Hamid O, Lutzky J et al: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. Journal of Clinical Oncology 2019, 37(15_suppl):2518-2518.CrossRef
99.
Jazaeri AA, Zsiros E, Amaria RN, Artz AS, Edwards RP, Wenham RM, Slomovitz BM, Walther A, Thomas SS, Chesney JA et al: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Journal of Clinical Oncology 2019, 37(15_suppl):2538-2538.CrossRef
100.
Chiappori A, Williams CC, Creelan BC, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Chen D-T, Beg AA, Boyle TA et al: Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. Journal of Clinical Oncology 2018, 36(15_suppl):9089-9089.CrossRef
101.
Powderly JD, Souza PLd, Gutierrez R, Horvath L, Seitz L, Ashok D, Park A, Walters MJ, Karakunnel JJ, Berry W et al: AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: preliminary results from ongoing phase I studies. Journal of Clinical Oncology 2019, 37(15_suppl):2604-2604.CrossRef
102.
Collins JM, Heery CR, Donahue RN, Palena C, Madan RA, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL, Bilusic M: Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):3091-3091.CrossRef
103.
Bermejo IM, Jaffee EM, Davar D, Cardarelli J, Williams D, Phillips P, Carleton M, Zhou M, Henau OD, Monga M et al: Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. Journal of Clinical Oncology 2018, 36(15_suppl):TPS3109-TPS3109.CrossRef
104.
Kluger H, Weiss SA, Olszanski AJ, Schuchter L, Linette GP, Garland L, Iannotti NO, Johnson M, Avsar E, Srivastava MK, et al. Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Research. 2019;79(13 Supplement):CT089.
105.
Grilley-Olson JE, Curti BD, Smith DC, Goel S, Gajewski T, Markovic S, Rixe O, Bajor DL, Gutierrez M, Kuzel T et al: SEA-CD40, a non-fucosylated CD40 agonist: interim results from a phase 1 study in advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):3093-3093.CrossRef
106.
Diab A, Hurwitz ME, Cho DC, Papadimitrakopoulou V, Curti BD, Tykodi SS, Puzanov I, Ibrahim NK, Tolaney SM, Tripathy D et al: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: preliminary phase 1/2 results of PIVOT. Journal of Clinical Oncology 2018, 36(15_suppl):3006-3006.CrossRef
107.
Vaena DA, Chaves J, Vogelzang NJ, Matrana MR, Gabayan AE, Riese MJ, Cho DC, Tagliaferri MA, Zalevsky J, Xie S et al: PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):TPS3115-TPS3115.CrossRef
108.
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704.PubMedPubMedCentralCrossRef
109.
Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clinical Cancer Research. 2014;20(1):221–32.PubMedCrossRef
110.
Spicer J, Provencio M, Garrido Lopez P, Bosch-Barrera J, de Castro Carpeño FJ, Felip E, Trigo J, Viteri S, Coart E, Schmidt E et al: 180TiPAn open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer. Annals of Oncology 2019, 30(Supplement_2).
111.
Villaruz L, Schneider B, Bauer T, Spira A, D'Amato G, Wasser J, Balmanoukian A, Lara P, Olszanski A, Gajewski T et al: OA05.02 Epacadostat plus pembrolizumab in patients with non-small cell lung cancer: phase 1/2 results from ECHO-202/KEYNOTE-037. Journal of Thoracic Oncology 2018, 13(10):S330.CrossRef
112.
Hyman DM, Brana I, Spreafico A, Schram AM, Pandya NB, Hoffman K, Hallet R, Giblin P, Anido J, Ruano IH et al: A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):TPS2602-TPS2602.CrossRef
113.
Camidge DR, Gadgeel SM, Weems GA, Wilkins HJ, Johnson ML: A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer. Journal of Clinical Oncology 2018, 36(15_suppl):TPS9111-TPS9111.CrossRef
114.
Chow LQM, Gainor JF, Lakhani NJ, Chung HC, Lee K-W, Lee J, LoRusso P, Bang Y-J, Hodi FS, Fanning P et al: A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. Journal of Clinical Oncology 2019, 37(15_suppl):2514-2514.CrossRef
115.
Ghosh S, Sharma G, Travers J, Kumar S, Choi J, Jun HT, Kehry M, Ramaswamy S, Jenkins D: TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade Molecular Cancer Therapeutics 2019, 18(3):632-641.
116.
Davar D BP, Eroglu Z, et al:: A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma 2018 SITC Annual Meeting 2018.
117.
Doger B: Initial results from a Phase II study (TACTI 002) in metastatic non small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG 3 protein ) and pembrolizumab. 34th German Cancer Congress in Berlin 2020.
118.
Ramlau R, Kowalski D, Szczylik C, Szczęsna A, Wiatr E, Demas S, Chao H, Roszkowski-Sliz K. P2.06-006 Phase I/II dose escalation study of L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients: topic: phase I/II trials. Journal of Thoracic Oncology. 2017;12(1):S1071–2.CrossRef
119.
Rajan A, Strauss J, Orpia A, Gatti-Mays ME, Wagner E, Heery CR, Pico C, Gulley JL: A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer. Journal of Clinical Oncology 2018, 36(15_suppl):TPS9108-TPS9108.CrossRef
120.
Papachristofilou A, Hipp MM, Klinkhardt U, Fruh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7(1):38.PubMedPubMedCentralCrossRef
121.
Gandhi L, Aufiero Ramirez K, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Venhaus RR: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2018, 36(15_suppl):TPS9107-TPS9107.CrossRef
122.
Havel L, Kolek V, Pesek M, Cernovská M, Bartunkova J, Spisek R, Pecen L, Krasnopolskaya I, Zemanova M, Investigators S: Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: final analysis of phase II, open label, randomized, multicenter trial. Journal of Clinical Oncology 2019, 37(15_suppl):9039-9039.CrossRef
123.
Hu-Lieskovan S, Ott PA, Naing A, Besada RH, Gates SJ, Kohler VR, Curran RR, Bushway ME, Scherer J, Balogh KN, et al. Abstract 942: The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: association with clinical outcomes. Cancer Research. 2019;79(13 Supplement):942.
124.
Govindan R, Awad MM, Cleary LD, Moles MA, Gaynor R, Goldstein MJ, Spigel DR: An open-label, phase 1b study of NEO-PV-01 with pembrolizumab plus chemotherapy in patients with advanced or metastatic nonsquamous non-small cell lung cancer. Journal of Clinical Oncology 2018, 36(15_suppl):TPS3134-TPS3134.CrossRef
125.
Hecht JR, Goldman JW, Hayes S, Balli D, Princiotta MF, Dennie JG, Heyburn J, Sands T, Sheeri S, Petit R, et al. Safety and immunogenicity of a personalized neoantigen-listeria vaccine in cancer patients. Cancer Research. 2019;79(13 Supplement):CT007.
126.
Awad MM, Bruchec YL, Lu B, Miller J, Dumitru CD, Spira AI: Phase Ib study: selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2019, 37(15_suppl):9029-9029.CrossRef
127.
Gandhi L, Janne PA, Opyrchal M, Ramalingam SS, Rybkin II, Hafez N, Raez LE, Gabrilovich D, Wang F, Ordentlich P et al: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. Journal of Clinical Oncology 2018, 36(15_suppl):9036-9036.CrossRef
128.
Saltos AN, Tanvetyanon T, Williams CC, Haura EB, Creelan BC, Antonia SJ, Tchekmedyian N, Goas K, Mamplata T, Thapa R et al: Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC). Journal of Clinical Oncology 2018, 36(15_suppl):9046-9046.CrossRef
129.
Patnaik A, Carvajal RD, Komatsubara KM, Britten CD, Wesolowski R, Michelson G, Alcantar O, Zhang C, Powell B, Severson P et al: Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors. Journal of Clinical Oncology 2018, 36(15_suppl):2550-2550.CrossRef
130.
Juergens RA, Chu QS, Renouf DJ, Laurie SA, Purcea D, McWhirter E, Arndt D, Gelmon KA, Hilton J, Gavillet B et al: A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. Journal of Clinical Oncology 2019, 37(15_suppl):2599-2599.CrossRef
Metadata
Title
Emerging therapeutic agents for advanced non-small cell lung cancer
Authors
Ruqin Chen
Rami Manochakian
Lauren James
Abdel-Ghani Azzouqa
Huashan Shi
Yan Zhang
Yujie Zhao
Kexun Zhou
Yanyan Lou
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2020
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-00881-7

Other articles of this Issue 1/2020

Journal of Hematology & Oncology 1/2020 Go to the issue

Research

The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia

Research

The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017

Rapid communication

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Letter to the Editor

Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1

Research

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Research

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits